Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has issued an announcement.
Resmed has scheduled the release of its financial and operational results for the second quarter of fiscal 2026 for January 29, 2026, after the close of trading on the New York Stock Exchange, followed by a management webcast to discuss the performance. The webcast, accessible exclusively via the company’s investor relations website, will provide investors and other stakeholders with detailed insight into quarterly results, with on-demand replay options available online and via phone, underscoring Resmed’s ongoing investor communication efforts and transparency around its financial and operational trajectory.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc., listed on the NYSE and ASX under the ticker RMD, operates in the medical technology and digital health sector, focusing on AI-powered solutions for sleep and respiratory care. The company develops cloud-connected devices and intelligent software that support personalized, home-based healthcare for millions of patients across 140 countries, with a particular emphasis on improving sleep health and breathing outcomes.
Average Trading Volume: 1,169,693
Technical Sentiment Signal: Buy
Current Market Cap: A$54.12B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.